KEYNOTE-716: Longer follow up supports pembrolizumab use in stage IIB/IIC melanoma

Tumour Treating Fields therapy extends OS for mNSCLC after plantinum failure

Primary mediastinal B-cell lymphoma: Radiotherapy superfluous post-chemoimmunotherapy

ASCO 2023: Highlights and analysis

ASCO 2023: Latest in PARP inhibitors in prostate cancer

Concurrent chemoradiotherapy followed by adjuvant cisplatin-gemcitabine improves PFS in N2-3 nasopharyngeal carcinoma

Talazoparib plus enzalutamide shows improvement in PFS over standard of care in firstline HRR mCRPC

Axi-cel improves survival in early r/r large B-cell lymphoma

CDK4/6 inhibitors added to first line show no greater benefit when compared to their use in second line therapy in HR+, HER2- ABC

Prognostic value of HER2-low status in breast cancer: A systematic review and meta-analysis

Extended lymph node removal does not benefit patients with clinically localised muscle-invasive bladder cancer

Dostarlimab chemo combination for primary advanced or recurrent endometrial cancer